Abstract:In cancer progression, abnormal AXL expression can promote tumor growth, metastasis, and chemotherapy resistance, while MER can identify apoptotic cancer cells and induce immune suppression in the tumor microenvironment. Combining AXL and MER inhibitors could generate a synergistic effect, enhancing antitumor responses, and further suppressing resistance formed by monotherapy with AXL selective or MER selective inhibitors. According to the explicit function of AXL and MER, the development of dual AXL and MER inhibitors may provide tremendous advantages to cancer patients. Drawing on our experience in the discovery of an anti-EGFR and anti-HER2 clinical candidate, we introduced several AXL-active and MER-active pharmacophores into DBPR112. Furthermore, we modified the scaffold and the solubilizing groups to improve the drug-like properties. Our comprehensive structure-activity relationship study led to the discovery of several potent dual AXL and MER inhibitors. Among approximately 200 synthesized compounds, BPR5K230 demonstrated strong inhibitory activities against AXL and MER, along with favorable oral bioavailability (F% = 55%) and promising in vivo antitumor effects in various mouse xenograft models, including MDA-MB-231, 4T1, and MC-38 tumor models. BPR5K230 effectively addressed sorafenib resistance in the Hepa 1-6 model and exhibited significant synergistic antitumor effects when combined with an anti-PD-L1 antibody in the EMT-6 model. As a result, BPR5K230 represents a promising dual AXL/MER kinase inhibitor, and further preclinical evaluation is underway for its development as a potential anticancer and immune-modulating drug. Citation Format: Hsing-Pang Hsieh, Mu-Chun Li, Wan-Ching Yen, Su-Ying Wu, Teng-Kuang Yeh, Ching-Chuan Kuo, Shau-Hua Ueng, Han-Chung Wu. Discovery of novel AXL and MER inhibitors as potential anticancer and immunomodulatory drugs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1809.

Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment

Abstract 1809: Discovery of novel AXL and MER inhibitors as potential anticancer and immunomodulatory drugs

Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor

Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors As a Promising Strategy for Cancer Therapy

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

Discovery of IDO1 and DNA Dual Targeting Antitumor Agents

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In Vivo Target Engagement

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor.

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

Small Molecules Simultaneously Inhibiting P53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (hdacs): Discovery of Novel Multitargeting Antitumor Agents

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers

Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.

Design, Synthesis and Biological Evaluation of Novel MDH Inhibitors Targeting Tumor Microenvironment

Discovery of Novel and Potent Dual-Targeting AXL/HDAC2 Inhibitors for Colorectal Cancer Treatment Via Structure-Based Pharmacophore Modelling, Virtual Screening, and Molecular Docking, Molecular Dynamics Simulation Studies, and Biological Evaluation